Abstract:Pharmaceuticals are recognised among emerging contaminants, particularly in water. They have the potential to alter ecosystem dynamics, with notable examples including hormone-induced feminization of male fish and disruptions to oogenesis in invertebrates. To assess the risk posed by pharmaceuticals, it is essential to understand their amount (via Measured Environmental Concentrations MEC) and their actual effects on target species (via Predicted No Effect Concentrations PNEC). Recently, many studies have aimed to collect MEC data from around the world, but a comprehensive overview is still lacking. Thus, the objective of this study is to provide a comprehensive overview by examining recently published literature on MEC data for a wide range of pharmaceuticals. Additionally, to enable risk assessment, this study also reviewed the published literature on PNEC data and integrated it with existing databases. A total of 315 substances were selected for MEC data extraction, with the inclusion of 56 articles. The most frequently monitored locations were Cadiz Bay in Spain (90 samples), the River Thames in the UK (51), and Hrdějovice in the Czech Republic (49). Most MEC samples were collected from surface water (N=325), influent wastewater treatment plants (WWTP) (205), and effluent WWTP (118). Based on PNEC values, risk analysis identified 81 pharmaceuticals as high-risk, with the highest risk values for propranolol (risk quotient [RQ]: 29,450,000), diclofenac (395,920), and 17alpha-ethinylestradiol (95,946). Additionally, the ATC classes with the most high-risk substances were anti-infectives (J), nervous system agents (N), cardiovascular agents (C), antineoplastic agents (L), analgesics (M), and sex hormones (G). The findings of this study highlight the widespread impact of pharmaceuticals across the globe and the involvement of multiple therapeutic classes. To move beyond the current point-in-time overview, which is limited to specific locations and sampling periods, systems for continuous monitoring of pharmaceuticals should be developed. This could involve the creation of resource-efficient methods and the integration of sampling data with estimation models. Furthermore, these results could serve as a starting point for developing and implementing actions to prevent and mitigate the environmental impact of pharmaceuticals.

Assessing the impact of antineoplastic drugs in the aquatic environment: State of the art and future perspective for freshwater organisms

Environmental Hazard of anticancer drugs: State of the art and future perspective for marine organisms

Anticancer drugs in the aquatic ecosystem: Environmental occurrence, ecotoxicological effect and risk assessment

Contributions towards the hazard evaluation of two widely used cytostatic drugs

New insights on cytostatic drug risk assessment in aquatic environments based on measured concentrations in surface waters

Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?

Treatment-driven removal efficiency, product formation, and toxicity evolution of antineoplastic agents: Current status and implications for water safety assessment

Predicted concentrations of antineoplastic drugs in the aquatic environment: The case of Ría de Vigo (NW, Spain)

Hazard assessment of antineoplastic drugs and metabolites using cytotoxicity and genotoxicity assays

Anti-cancer drugs in aquatic environment can cause cancer: Insight about mutagenicity in tadpoles

From bacteria to fish: ecotoxicological insights into sulfamethoxazole and trimethoprim

Antineoplastic compounds in the environment—substances of special concern

Are cytostatic drugs in surface waters a potential threat?

Environmental impact and biological removal processes of pharmaceutically active compounds: The particular case of sulfonamides, anticonvulsants and steroid estrogens

The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects

Amitriptyline ecotoxicity in Danio rerio (Hamilton, 1822) embryos – similar toxicity profile in the presence of nanoplastics

Non-Steroidal Anti-Inflammatory Drugs in the Aquatic Environment and Bivalves: The State of the Art

Potential environmental toxicity of sewage effluent with pharmaceuticals

Review: ecotoxicity of organic and organo-metallic antifouling co-biocides and implications for environmental hazard and risk assessments in aquatic ecosystems

Toxicity of selected pharmaceuticals and their mixtures to the aquatic indicators Daphnia magna and Aliivibrio fischeri

Single and mixture toxicity of four pharmaceuticals of environmental concern to aquatic organisms, including a behavioral assessment